You are here » Home » Companies » Company Overview » Hindustan Bio Sciences Ltd

Hindustan Bio Sciences Ltd.

BSE: 532041	Sector: Health care
NSE: N.A.	ISIN Code: INE597C01013

BSE 00:00 | 02 Mar

5.32

0
(0.00%)

OPEN

5.32

HIGH

5.32

LOW

5.32

NSE 05:30 | 01 Jan

Hindustan Bio Sciences Ltd

Add to Watchlist | Add to Portfolio

OPEN	5.32
PREVIOUS CLOSE	5.32
VOLUME	18478
52-Week high	5.60
52-Week low	3.23
P/E
Mkt Cap.(Rs cr)	5
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	5.32
CLOSE	5.32
VOLUME	18478
52-Week high	5.60
52-Week low	3.23
P/E
Mkt Cap.(Rs cr)	5
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Hindustan Bio Sciences Ltd. (HINDBIOSCIENCE) - News Sector

Glenmark gets USFDA nod to market generic medication to treat schizophrenia

11.53 am | 20 Mar 2023 | Press Trust of India

Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic product used to treat schizophrenia ...
India was world's No. 1 in handling Covid: Apollo Hospitals founder

10.54 pm | 19 Mar 2023 | Business Standard

In a Q&A, Prathap Chandra Reddy talks about the need to focus on medical tourism and medical education to meet the demand of 18 million professionals ...
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

10.47 am | 17 Mar 2023 | Business Standard

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

10.47 am | 17 Mar 2023 | Business Standard

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore

11.30 pm | 16 Mar 2023 | Business Standard

In January Eris had bought some derma brands from Glenmark Pharma as well
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Glenmark Pharma receives USFDA approval for generic antibiotic drug

2.19 pm | 14 Mar 2023 | Press Trust of India

Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic antibiotic drug. The company has r...
NTPC, PFC: 5 F&O stocks see long OI build-up; Here's how to trade in them

11.26 am | 13 Mar 2023 | Business Standard

Build-up of long OI in general indicates that traders are expecting the price of the underlying stock or index to gain in the near-term.
Marksans Pharma gets USFDA nod for generic version of Famotidine tablets

2.35 pm | 10 Mar 2023 | Press Trust of India

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Famotidine tablets indicated...
Natco launches additional strengths of generic version of Revlimid in US

2.01 pm | 10 Mar 2023 | Press Trust of India

Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, ...
Alembic Pharma gets USFDA nod to market generic antidepressant drug

2.45 pm | 9 Mar 2023 | Press Trust of India

Alembic Pharmaceuticals on Thursday said it has received an approval from the US health regulator to market a generic antidepressant medication in the...